Dr. Sonali Smith discusses the newest developments in the treatment of CML.
Highlighting Developments and Informing Treatment Planning in CLL Care
Clinical guidelines aimed at both clinicians and patients seek to educate and include both parties in clinical decision-making processes.
Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy
Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.
Improved Outcomes in MRD-Negative R/R B-ALL with Obe-Cel Treatment
Results from the FELIX study showed that obe-cel induces high rates of MRD-negative remission in relapsed/refractory B-ALL, leading to improved EFS and OS.
Immunotherapy Approaches in AML
Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.
Obe-Cel Is Effective in R/R B-ALL Patients with Low CAR-HT Risk
Obe-cel shows efficacy in R/R B-ALL, especially in those with a favorable CAR-HT risk profile, according to data from the phase 1/2 FELIX study.
Tuspetinib Triplet Therapy Achieves Early Responses in AML
A total of 3 patients with AML treated with the lowest dose of tuspetinib at 40 mg completed the first cycle of treatment with no dose-limiting toxicities.
